Lilly’s Donanemab Wins India Approval For Alzheimer’s

This article was first published on: GuruFocus.

Eli Lilly (NYSE:LLY) I achieved a meaningful international connection India’s drug regulator won after the company approved donanemab, an Alzheimer’s treatment for people in the very early stages of the disease. Lilly expects the drug to be available in the Indian market within the next few months, making the therapy a major mainstay outside the US.

Pricing is still a big open question. Lilly is yet to share its India plans, but the drug currently costs around $32,000 per year in the US, which translates to roughly Rs 28.34 lakh. The final price for India will depend on factors such as local production, import duties and regulatory requirements, all of which may determine how accessible the treatment will be once it begins.

The approval comes at a time when awareness about Alzheimer’s and early detection is growing rapidly in India, making the country a key market for new treatments such as donanemab.

For investors, this marks another step in Lilly’s global rollout. The most important thing to watch next is how the company approaches pricing and availability ahead of launch.